An open-label single-arm, phase II trial of zalutumumab, a human monoclonal anti-EGFR antibody, in patients with platinum-refractory squamous cell carcinoma of the head and neck (Q38432573)

From Wikidata

Jump to navigation Jump to search

scientific article published on 09 April 2014

Language	Label	Description	Also known as
English	An open-label single-arm, phase II trial of zalutumumab, a human monoclonal anti-EGFR antibody, in patients with platinum-refractory squamous cell carcinoma of the head and neck	scientific article published on 09 April 2014

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

An open-label single-arm, phase II trial of zalutumumab, a human monoclonal anti-EGFR antibody, in patients with platinum-refractory squamous cell carcinoma of the head and neck (English)

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

phase II clinical trial

0 references

squamous cell carcinoma

1 reference

based on heuristic

inferred from title

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24714973%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24714973%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24714973%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Vassiliki Saloura

1

object named as

Vassiliki Saloura

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24714973%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

author name string

Salem Billan

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24714973%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Steen Lisby

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24714973%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Thomas C Gauler

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24714973%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

publication date

9 April 2014

1 reference

Europe PubMed Central

PubMed publication ID

3 September 2017

Cancer Chemotherapy and Pharmacology

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24714973%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

73

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24714973%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24714973%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

1227-1239

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24714973%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

https://scigraph.springernature.com/pub.10.1007/s00280-014-2459-z

0 references

Platinum-based chemotherapy plus cetuximab in head and neck cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2459-Z

21 January 2018

Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2459-Z

21 January 2018

Expression and mutation analysis of epidermal growth factor receptor in head and neck squamous cell carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2459-Z

21 January 2018

EGFR, HER2, and HER3 expression in laryngeal primary tumors and corresponding metastases

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2459-Z

21 January 2018

RETRACTED: The antibody zalutumumab inhibits epidermal growth factor receptor signaling by limiting intra- and intermolecular flexibility

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2459-Z

21 January 2018

Dual mode of action of a human anti-epidermal growth factor receptor monoclonal antibody for cancer therapy

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2459-Z

21 January 2018

Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: an open-label, randomised phase 3 trial

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2459-Z

21 January 2018

Association of progression-free survival, overall survival, and patient-reported outcomes by skin toxicity and KRAS status in patients receiving panitumumab monotherapy.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2459-Z

21 January 2018

Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining?

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2459-Z

21 January 2018

Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2459-Z

21 January 2018

Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2459-Z

21 January 2018

United States Food and Drug Administration Drug Approval summary: Gefitinib (ZD1839; Iressa) tablets

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2459-Z

21 January 2018

Interstitial lung disease associated with drug therapy

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2459-Z

21 January 2018

Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2459-Z

21 January 2018

Targeting EGFR resistance networks in head and neck cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2459-Z

21 January 2018

Protein-intrinsic and signaling network-based sources of resistance to EGFR- and ErbB family-targeted therapies in head and neck cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2459-Z

21 January 2018

Molecular phenotype predicts sensitivity of squamous cell carcinoma of the head and neck to epidermal growth factor receptor inhibition

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2459-Z

21 January 2018

New strategies in head and neck cancer: understanding resistance to epidermal growth factor receptor inhibitors

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2459-Z

21 January 2018

Open-Label, Uncontrolled, Multicenter Phase II Study to Evaluate the Efficacy and Toxicity of Cetuximab As a Single Agent in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Who Failed to Respond to Platinum-Base

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2459-Z

21 January 2018

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38432573&oldid=1797648425"